AstraZeneca and Neurimmune to develop and commercialise NI006
Investigational human monoclonal antibody in Phase Ib development for the treatment of transthyretin amyloid cardiomyopathy, a systemic, progressive and fatal condition
Investigational human monoclonal antibody in Phase Ib development for the treatment of transthyretin amyloid cardiomyopathy, a systemic, progressive and fatal condition
Biogen paid Ionis a US $ 60 million one-time upfront payment
Molflu is expected to be available from early next week in pharmacies throughout the country with a particular focus on states with a high caseload of Covid-19.
The Subject Expert Committee has recommended grant of permission to conduct Phase 3 trials under certain conditions
Aim of the virtual conference is to facilitate Indian Pharma Industry adopt Green & Sustainable Chemistry as a tool to enhance Economic & Environmental Competitiveness
The newly launched centre in Mumbai is part of the company’s ambition to be present in 100 cities across the country within two years.”
G42 Healthcare and AstraZeneca will work closely together to explore real-world evidence and conduct clinical trials through IROS – the first-of-its-kind Contract Research Organization (CRO) in the UAE
Zeebon is the largest diagnostics services provider in North-Eastern states
It plans to deliver over 300 million doses to the Indian government
The company will market it under the brand name Molflu
Subscribe To Our Newsletter & Stay Updated